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Review of Harmful Gastrointestinal Effects of Carrageenan in Animal
Experiments
Joanne K. Tobacman
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During the latter half of the twentieth
century, inflammatory bowel disease and
gastrointestinal malignancy have been major
causes of morbidity and mortality in the
United States. Even with improvements in
treatment and cancer screening, colorectal
cancer remains the second leading cause of
cancer mortality in the United States. The
Western diet has been considered a possible
source of inflammatory bowel disease and
colorectal malignancy, and intensive efforts
have been undertaken to study the impact of
specific constituents of the Western diet,
such as ﬁber and fat (1–3). 
One food additive, carrageenan, has been
associated with induction and promotion of
intestinal neoplasms and ulcerations in
numerous animal experiments; however, car-
rageenan remains a widely used food addi-
tive. In 1982, the International Agency for
Research on Cancer (IARC) (4) designated
degraded carrageenan as Group 2B, noting
sufﬁcient evidence for the carcinogenicity of
degraded carrageenan in animal models to
infer that “in the absence of adequate data
on humans, it is reasonable, for practical
purposes, to regard chemicals for which
there is sufﬁcient evidence of carcinogenicity
in animals as if they presented a carcinogenic
risk to humans” (p. 90). The National
Research Council has noted this designation
for degraded carrageenan in their 1996
monograph (5). Recognizing the impact of
carrageenan in animal models, several
European and British investigators have
advised against the continued use of car-
rageenan in food (6–11). Several reports
have called attention to the problems associ-
ated with carrageenan consumption (6–11). 
Extracted from red seaweed, carrageenan
has been used in food products for centuries
and was patented as a food additive for use in
the United States in the 1930s. It has been
used widely as a food additive, contributing to
the texture of a variety of processed foods. It
has also been used as a laxative, as treatment
for peptic ulcer disease, and as a component
of pharmaceuticals, toothpaste, aerosol sprays,
and other products (12–15). In 1959, car-
rageenan was granted GRAS (Generally
Regarded as Safe) status in the United States.
GRAS substances are permitted to be incor-
porated into food products as long as good
manufacturing processes are used and the
substance is used only in sufﬁcient quantity to
achieve the desired effect (16,17). 
In the United States, the status of car-
rageenan was reconsidered by the Food and
Drug Administration, and an amendment to
the Code of Federal Regulations for the food
additive carrageenan was proposed in 1972
(18). To diminish the public’s exposure to
degraded carrageenan, the amendment sup-
ported inclusion of an average molecular
weight for carrageenan of 100,000 and a
minimum viscosity of 5 centipoises (cps)
under specified conditions. However, the
actual regulation was not amended, although
several publications indicated that it had
been modified (7,8,19–23). In 1979, the
proposal to include the average molecular
weight requirement of 100,000 and the asso-
ciated viscosity requirement in the Code of
Federal Regulations was withdrawn. It was
anticipated that a new rule-making proposal
on carrageenan that would comprehensively
address all food safety aspects of carrageenan
and its salts would be published in about a
year, but this has not been forthcoming
(24,25). The proposal withdrawal referred to
interim specifications for food-grade car-
rageenan using the Food Chemical Codex;
these include a viscosity stipulation, but no
average molecular weight requirement (26).
In the Food Chemicals Codex and sup-
plements, carrageenan is described with
attention to specific requirements for its
identification and tests of its properties,
including its sulfate content, heavy metal
content, solubility in water, content of acid-
insoluble matter, and viscosity [a 1.5% solu-
tion is to have viscosity ≥ 5 cps at 75°C]
(26,27). Although the viscosity is stipulated,
viscosity may not adequately protect food-
grade carrageenan from contamination by
the lower molecular weight degraded car-
rageenans that IARC has denoted as Group
2B. Because undegraded carrageenan may
have molecular weight in the millions, the
actual viscosities of commercial car-
rageenans range from about 5 to 800 cps
when measured at 1.5% at 75°C (14).
Native carrageenan has molecular weights of
1.5 × 106–2 × 107 (28); poligeenan or
degraded carrageenan is described as having
average molecular weight of 20,000–30,000
(4). The average molecular weight of
poligeenan has been described elsewhere as
10,000–20,000, but extending up to 80,000
(29). Food-grade carrageenan has been
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In this article I review the association between exposure to carrageenan and the occurrence of colonic
ulcerations and gastrointestinal neoplasms in animal models. Although the International Agency for
Research on Cancer in 1982 identiﬁed sufﬁcient evidence for the carcinogenicity of degraded car-
rageenan in animals to regard it as posing a carcinogenic risk to humans, carrageenan is still used
widely as a thickener, stabilizer, and texturizer in a variety of processed foods prevalent in the
Western diet. I reviewed experimental data pertaining to carrageenan’s effects with particular atten-
tion to the occurrence of ulcerations and neoplasms in association with exposure to carrageenan. In
addition, I reviewed from established sources mechanisms for production of degraded carrageenan
from undegraded or native carrageenan and data with regard to carrageenan intake. Review of these
data demonstrated that exposure to undegraded as well as to degraded carrageenan was associated
with the occurrence of intestinal ulcerations and neoplasms. This association may be attributed to
contamination of undegraded carrageenan by components of low molecular weight, spontaneous
metabolism of undegraded carrageenan by acid hydrolysis under conditions of normal digestion, or
the interactions with intestinal bacteria. Although in 1972, the U.S. Food and Drug Administration
considered restricting dietary carrageenan to an average molecular weight > 100,000, this resolution
did not prevail, and no subsequent regulation has restricted use. Because of the acknowledged car-
cinogenic properties of degraded carrageenan in animal models and the cancer-promoting effects of
undegraded carrageenan in experimental models, the widespread use of carrageenan in the Western
diet should be reconsidered. Key words: carcinogenesis, carrageenan, carrageenase, diet, furcelleran
(furcellaran), hydrolysis, inﬂammatory bowel disease, nutrition, poligeenan, promoter, sulfated poly-
saccharide. Environ Health Perspect 109:983–994 (2001). [Online ________]
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Reviewdescribed as having average molecular weight
of 200,000–400,000 (29), and elsewhere as
having molecular weight of 100,000–800,000
(19).  Furcelleran (or furcellaran), a
degraded carrageenan of molecular weight
20,000–80,000, has a sulfate content of
8–19% (12,17). No viscosity or minimum
average molecular weight was designated for
furcelleran in the 1972 or 1979 Federal
Register documents (18,24). In the Food
Chemical Codex (fourth edition), a 1.5%
solution of furcelleran at 75°C is described as
having minimum viscosity of 5 cps (27). 
Today, carrageenan is still included
among the food additives designated GRAS
in the Code of Federal Regulations. The
stipulations for its use include the following:
a) it is a sulfated polysaccharide, the domi-
nant hexose units of which are galactose and
anhydrogalactose; b) range of sulfate content
is 20–40% on a dry-weight basis; c) the food
additive is used or intended for use in the
amount necessary for an emulsifier, stabi-
lizer, or thickener in foods, except for those
standardized foods that do not provide for
such use; d) to assure safe use of the additive,
the label and labeling of the additive shall
bear the name of the additive, carrageenan.
Also included are similar standards for car-
rageenan salts and for furcelleran and fur-
celleran salts (30). In 1999–2000, approved
uses for carrageenan were extended to
include additional incorporation into food
and medicinal products, including both
degraded and undegraded carrageenan in
laxatives (31–33).
For use in experimental models, degraded
carrageenan (poligeenan) is derived from car-
rageenan by acid hydrolysis, frequently by a
method developed by Watt et al. (34). This
method is expected to yield a degraded car-
rageenan of average molecular weight
20,000–30,000 (35). Experiments demon-
strate that reaction conditions similar to
those of normal digestion can lead to 
the formation of degraded carrageenan
(9–11). In addition, experimental data have
revealed the contamination of food-grade
carrageenan by substantial amounts of
degraded carrageenan (10). Also, some bacte-
ria are known to hydrolyze carrageenan and
form low molecular weight derivatives
(36–40). 
The sections that follow and the accom-
panying tables summarize many experimen-
tal observations with regard to the intestinal
effects of carrageenan. In addition, I review
possible mechanisms for production of
degraded carrageenan from undegraded car-
rageenan under physiologic conditions, as
well as evidence that provides a basis for the
mechanism of carrageenan’s effects and for
the reconsideration of the safety of car-
rageenan in the human diet.
Characteristics of
Carrageenan
Three forms of carrageenan predominate,
known as kappa, iota, and lambda. All have
similar D-galactose backbones (alternating α-
1,3 to β-1,4 linkages), but they differ in
degree of sulfation, extent of branching,
solubility, cation binding, and ability to
form gels under different conditions. λ-
Carrageenan is the least branched and the
least gel forming; it is readily soluble at cold
temperatures, in contrast to κ- or ι-car-
rageenan. Table 1 presents some of the basic
characteristics of κ, ι, and λ carrageenan
(4,12–15,20–22,31–33,41–44)
In addition to food additive uses, car-
rageenan has been used in cosmetics, pesti-
cides, and pharmaceuticals, as well as in
toothpaste and room deodorizers. It has
been used as a treatment of ulcers and as an
emulsifier in mineral oil laxatives, liquid
petrolatum, and cod liver oil. However, its
predominant role has been in food prepara-
tions, in which it is used across a wide vari-
ety of food groups because of its ability to
substitute for fat and its ability to combine
easily with milk proteins to increase solubil-
ity and improve texture. Hence, it is used in
low-calorie formulations of dietetic bever-
ages, infant formula, processed low-fat
meats, whipped cream, cottage cheese, ice
cream, and yogurt, as well as in other prod-
ucts. From its original use several centuries
ago as a thickener in Irish pudding and its
incorporation into blancmange, the food
additive use has extended widely and cuts
across both low-fat and high-fat diets. It is
often combined with other gums, such as
locust bean gum, to improve the texture of
foods (12–14,22,41,42). 
In 1977, data obtained by the survey of
industry on the use of food additives pro-
duced an estimate of daily carrageenan
intake of 100 mg for individuals older than
2 years. The 1971 survey of industry had
indicated that formula-fed infants in the ﬁrst
5 months of life had an intake of 108
mg/day (21,43). Informatics, Inc., in a
report prepared for the Food and Drug
Administration, cited daily carrageenan con-
sumption of 45 mg (19); this is similar to
the reported intake of 50 mg/day of car-
rageenan in France (45). Nicklin and Miller
(20) reported intake of 0–1.5 g/day, depend-
ing on choice of diet and total food con-
sumed. Although the Food and Nutrition
Board of the National Research Council of
the National Academy of Sciences of the
United States in 1971 initially estimated 367
mg/day for carrageenan intake for individu-
als older than 2 years in the United States,
this was subsequently revised to 11 mg/day.
The wide range of estimates may be attrib-
uted to inconsistencies in how industry has
reported carrageenan production and con-
sumption data, variation in processed food
formulations with regard to extent of incorpo-
ration of carrageenan, and changes in use of
carrageenan in nonfood products. Daily indi-
vidual consumption of between 50 mg/day
and 100 mg/day is consistent with total con-
sumption in the United States of 7,700 met-
ric tons, as estimated for 1997 (46). 
The content of carrageenan in several com-
monly consumed food products is summarized
Review • Tobacman
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Table 1. Characteristics of carrageenan (4,12–15,27,28,41–49).
Chemical composition Hydrocolloid composed of α-D-1,3 and β-D-1,4 galactose residues that are sulfated at
up to 40% of the total weight. Strong negative charge over normal pH range.
Associated with ammonium, calcium, magnesium, potassium, or sodium salts.
Solubility λ is readily soluble in cold or hot aqueous solution; κ is soluble in hot solution;
treatment of aqueous solution with potassium ion precipitates κ-carrageenan.
Gel formation λ does not form gels; λ and ι form right-handed helices; potassium chloride promotes
gel formation of κ; calcium ion promotes gel formation of ι.
Metabolism Hydrolysis of glycosidic linkages at lower pH, especially pH ≤ 3.0; also desulfation by
sulfatases.
Viscosity Near logarithmic increase in viscosity with increasing concentration. Viscosity of 
food-grade carrageenan deﬁned as not less than 5 cps at 75°C for a 1.5% 
solution; viscosity ranges from 5 to 800 cps for 1.5% solution at 75°C. 
Source Red algae; predominantly aqueous extraction from Chondrus, Gigartina, and various
Eucheuma species.
Molecular weight Discrepancies in deﬁnitions. Native carrageenan reported to have average 
molecular weight of 1.5 × 106 – 2 × 107; food-grade carrageenan reported as
100,000–800,000 or 200,000–400,000. Degraded carrageenan (poligeenan) has 
average molecular weight of 20,000–30,000; furcellaran has average
molecular weight 20,000–80,000.
Properties λ and κ combine easily with milk proteins to improve solubility and texture; serve as 
thickening agent, emulsiﬁer, stabilizer. 
Synergistic effects With locust bean gum, increase in gel strength. Other hydrocolloids may also affect 
gel strength and cohesiveness.
Concentration in  0.005–2.0% by weight.
food products
Major uses Milk products, processed meats, dietetic formulations, infant formula, toothpaste, 
cosmetics, skin preparations, pesticides, laxativesin Table 2. Because manufacturing practices
vary and change over time and the food formu-
lae are proprietary, carrageenan content is indi-
cated by a range (12,13,47–49). The content
is expressed as the percent by weight of car-
rageenan used in the production of the food.
Experimental Results in
Animal Models 
Intestinal lesions after exposure to car-
rageenan in animal models. Table 3 summa-
rizes the laboratory investigations that
associate exposure to carrageenan with the
occurrence of intestinal lesions (50–93).
Several animals were tested, including guinea
pig, rat, monkey, mouse, rabbit, and ferret.
The guinea pig seemed most susceptible to
ulceration and the rat most susceptible to
malignancy. Many studies used exposure to
carrageenan in a drinking fluid, at concen-
trations generally of 1%. Some were feeding
studies, in which carrageenan was added to a
solid diet. Some studies used gastric or duo-
denal intubation to ensure intake at a speci-
fied level; however, this method may have
affected the way that carrageenan was
metabolized by gastric acid (74,82–84,91).
Feeding of carrageenan with milk may also
have affected study results, because car-
rageenan binds tightly to milk proteins
(caseins), affecting its metabolism (12–15,
22,41,42,47). The degraded carrageenan
used in most of the experiments had molec-
ular weight from 20,000 to 40,000. Several
major findings in relation to neoplasia and
ulceration were observed in these animal
studies. All of these studies observed the
effects of carrageenan in comparison to
appropriate control animals.
In the footnote to Table 3, several subdi-
visions of the table are indicated with citation
of the entries from the table. The subdivi-
sions include: a) studies in which carrageenan
alone induces abnormal proliferation or
malignancy, b) studies in which carrageenan
alone induces intestinal ulcerations, c) stud-
ies in which carrageenan appears to be a pro-
moter of malignancy in association with
another agent, d) studies using a rat model,
e) studies using a guinea pig model, f) studies
using degraded carrageenan, g) studies using
undegraded carrageenan, h) studies indicat-
ing uptake of carrageenan into an extrain-
testinal site(s), i) studies indicating intestinal
breakdown of carrageenan into lower molec-
ular weight forms, and j) studies demonstrat-
ing ulcerations in rats using degraded
carrageenan. In the table, the classiﬁcation of
the carrageenan used in the experiments as
κ, λ, or ι is indicated when this information
is clear from the original report. 
Neoplasia. Wakabayashi and associates
(72) demonstrated the appearance of colonic
tumors in 32% of rats fed 10% degraded
carrageenan in the diet for less than 24
months. The lesions included squamous cell
carcinomas, adenocarcinomas, and adeno-
mas. With exposure to 5% degraded car-
rageenan in drinking water, there was a
100% incidence of colonic metaplasia after
15 months. Metastatic squamous cell carci-
noma was observed in retroperitoneal lymph
nodes in this experiment. In addition,
macrophages that had metachromatic stain-
ing consistent with carrageenan uptake were
observed in liver and spleen.
Other studies have demonstrated the
development of polypoidal lesions and
marked, irreversible squamous metaplasia of
the rectal mucosa, the extent of which was
associated with duration and concentration
of carrageenan exposure (67,70). Oohashi et
al. (67) observed a 100% incidence of col-
orectal squamous metaplasia that progressed
even after degraded carrageenan intake was
discontinued in rats fed 10% degraded
carrageenan for 2, 6, or 9 months and sacri-
ﬁced at 18 months. 
Fabian et al. (84) observed adenomatous
and hyperplastic polyps as well as squamous
metaplasia of the anorectal region and the
distal colon in rats given 5% carrageenan as
a drinking fluid. Similarly, Watt and
Marcus (90) observed hyperplastic mucosal
changes and polypoidal lesions in rabbits
given carrageenan as drinking ﬂuid for 6–12
weeks at a concentration of 0.1–5%. Focal
and severe dysplasia of the mucosal epithe-
lium was observed in rabbits after 28
months of 1% degraded carrageenan in
their drinking ﬂuid (58). 
Promotion of neoplasia. Several studies
demonstrated an increased occurrence of
neoplasia in relation to exposure to unde-
graded or degraded carrageenan and associ-
ated exposure to a known carcinogen.
Experimental data with undegraded car-
rageenan included enhanced incidence of
colonic tumors in rats treated with
azoxymethane (AOM) and nitrosomethy-
lurea (NMU), when carrageenan was added
to the diet. Groups of rats received control
diet; control diet with 15% carrageenan;
15% carrageenan plus 10 injections of AOM
given weekly; carrageenan plus NMU;
NMU alone; and AOM alone. AOM or
NMU with carrageenan led to 100% inci-
dence of tumors, versus 57% with AOM
alone and 69% with NMU alone (p < 0.01).
Controls had 0%, and carrageenan alone led
to an incidence of 7%. In addition, when
undegraded carrageenan was combined with
AOM, there was a 10-fold increase in the
number of tumors per rat (73). (Figure 1) 
Using undegraded carrageenan as a solid
gel at concentration 2.5% for 100 days,
Corpet et al. (50) found that after exposure
to azoxymethane, there was promotion of
aberrant crypt foci by 15% (p = 0.019).
Exposure of rats to 6% undegraded car-
rageenan in the diet for 24 weeks, with 1,2-
dimethylhydrazine (1,2-DMH) injections
weekly, was associated with an increase in
tumors from 40% to 75% and with the
more frequent occurrence of larger and prox-
imal tumors (57). 
Degraded carrageenan in the diet of rats
at a 10% concentration in association with
exposure to 1,2-DMH weekly for 15 weeks
was associated with an increase in small
intestinal tumors from 20% to 50% and in
colonic tumors from 45% to 60% (64).
Iatropoulos et al. (77) found that in rats given
5% degraded carrageenan in the drinking
water for less than 30 weeks in association
with injections of 1,2-DMH weekly, there
were increases in poorly differentiated adeno-
carcinomas and in tumors of the ascending
and transverse colon, as well as increased pro-
liferation of cells in the deep glandular areas.
Several investigators have measured the
effect of carrageenan on thymidine incorpo-
ration and colonic cell proliferation. Wilcox
et al. (51) observed a 5-fold increase in
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Table 2. Range of content of carrageenan in some commonly consumed foods.
Food Percent carrageenan (g/100 g food) 
Bakery products 0.01–0.1
Chocolate milk 0.01–0.2
Cottage cheese 0.02–0.05
Frosting base mix 3–4
Ice cream, frozen custard, sherbets, etc. 0.01–0.05
Jams and jellies 0.5–1.2
Liquid coffee whitener 0.3
Pie ﬁlling 0.1–1.0
Pimento olive stufﬁng 2.0
Processed cheese 0.01–0.06
Processed meat or ﬁsh 0.2–1.0
Pudding (nondairy) 0.1–0.5
Relishes, pizza, barbecue sauces 0.2–0.5
Yogurt 0.2–0.5
Because manufacturing processes vary and there can be substitutions of one hydrocolloid for another, the content of
carrageenan for any individual product may differ from these estimates. Unpublished manufacturers’ data indicate that
these content estimates for processed cheese, frozen dairy dessert, cottage cheese, and jams and jellies are signifi-
cantly lower than current usage (4,13,14,47).thymidine kinase activity in colon cells with
5% undegraded or 5% degraded carrageenan.
There was an associated 35-fold increase in
proliferating cells in the upper third of crypts
with degraded carrageenan and an 8-fold
increase with undegraded carrageenan (51).
With 5% λ-undegraded carrageenan fed to
rats for 4 weeks, Calvert and Reicks (55)
observed a 4-fold increase in thymidine kinase
activity in the distal 12 cm of the colon (p <
0.001). Fath et al. (59) observed a 2-fold
increase in colonic epithelial cell proliferation,
Table 3. Experimental data related to intestinal effects of dietary carrageenan exposure.
Experiment
Type of Effects
carrageenan, Dose Additional Digestive/
molecular weight Animal  %CG (g/kg bw/day) Duration Route exposure systemic  Histopathologic changes Neoplastic changes Reference
1. Undegradeda,d Rat 10 27.4 8 days, Jelly AOM injection Less weight gain UCG jelly (10% × 8 days) (50)
sacriﬁced (5 mg/kg ip) with 2.5% CG did not initiate tumor.
at 30 days
Undegradeda,d Rat 0.25 0.2 100 days Liquid AOM injection UCG solid gel promoted
2.5 4 100 days Solid gel (20 mg/kg ip)  growth of aberrant crypt 
prior to CG foci (+15%; p = 0.019).
2. Undegraded ι,  Rat 0.5, 1.5, 5 ≤ 91 days Diet Epithelial cell loss, macrophage 5-Fold increase in  (51)
>100,000a,b inﬁltration, loss of crypts. thymidine kinase
Degraded ι, Rat 0.5, 1.5, 5 ≤ 91 days Diet activity in colon cells 
20,000a,b with 5% UCG or DCG.
35-Fold increase in 
proliferating cells in 
upper third of crypt
with DCG, 8-fold with
UCG.
3. Degraded ι, Guinea pig 2, 2.5, 5 7 days Drink Eicosapen- 2% led to FOB+ Cecal ulcerations; foamy  (52)
30,000c taenoic acid at 7 days; 5% led macrophages; small epithelial
(300 mg/kg/day) to 38% mortality ulcerations at 2 days.
at 14 days
4. Degraded, Guinea pig 3 5.8 2–3 days Drink Microscopic mucosal changes from  (35)
20,000–30,000c cecum to rectum; apparent macro-
molecule absorption by colonic
epithelium, macrophage inﬁltration,
macrophages with vacuoles.
5. Degradedc Guinea pig 1, 2, 3 2, 3, 4 2 weeks Drink 100% had cecal ulceration after  (53)
3% for 4 days; crypt abscesses.
6. Degradedc Rat ileal cell 0–1.5 g/L 19, 30, 54 hr Media Retarded cell growth (54)
monolayers caused cell death;
at 0.25g/L inhibited
DNA synthesis by 20%.
7. Undegraded λ, Rat 5 4 weeks Diet 3/8 had slight congestion  4-Fold increase in (55)
300,000a,b and erythema of distal colon. thymidine kinase
activity in distal
12 cm of colonic
mucosa.
8. Degraded ιc Rat, 5 4 months Drink Increased permeability to  (56)
Guinea pig 5 3 weeks Drink (3H) PEG-900; ulcerations in 
guinea pig, crypt abscesses, 
macrophage inﬁltration.
9. Undegraded κa,d Rat 6 0.8 24 weeks diet 1,2-DMH More tumors with  (57)
(20 mg/kg bw)  UCG than control diet
SC × 16 wks (75% vs. 40%); also larger,
more proximal tumors.
10. Degraded λa,b,c Rabbit 1 8 weeks, Drink Ulcerative lesions at 8 wks; at At 28 months, focal (58)
12 months, 12 months had chronic and severe glandular
28 months inﬂammatory changes. atypism; precancerous
changes seen.
11. Degradeda,b,c Mice 10 10 days Drink Bloody diarrhea Ulceration in proximal and distal  2-Fold increase in (59)
colon, with dilatation of cecum  colonic epithelial cell
and ascending colon. proliferation; increase
in labeling indices and
extension of proliferative
compartment to upper
third of crypt.
12. Degraded, Cultured rat 1 mg/10 mL 20 hr DCG and UCG nonmuta- (60)
(20,000–40,000), hepatocytes or genic in Salmonella
and  or intestinal 1 mg/100 mL 2 hr mutagenicity test; DCG non-
Undegradeda mucosal cells genotoxic by DNA repair test.
13. Undegraded  Rat  0.5 0.15–0.25 90 days Drink CG able to penetrate intestine;  (61)
κ, λ, and ιe CG in mesenteric lymph node,
and macrophages of villus and
lamina propria.
14. Degradedc Guinea pig 5 5 days Drink Small, superﬁcial ulcerations (62)
over mucosal surface of
cecum (1–111 ulcerations/cm2).
15. Degradedc Guinea pig 5 14 days Drink With ileo- Ulcerations in cecum and proximal (63)
transvers- colon in unoperated. Postprocedure,
ostomy crypt abscesses in rectum and 
ulcerations in distal colon and
rectum. Macrophage inﬁltration.
Continued, next page
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mal and distal colon and extensive increase of
the proliferative compartment in the proximal
colon to the upper third of the intestinal crypt,
after exposure of mice to 10% degraded car-
rageenan in drinking water for 10 days. 
Ulceration.  Many studies have
demonstrated significant ulceration of the
cecum and/or large intestine after oral
exposure to carrageenan in guinea pigs, rab-
bits, mice, rats, and rhesus monkeys
(34,35,53,56,58,59,62,63,65,68,70,71,75,
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Table 3. Continued
Experiment
Type of Effects
carrageenan, Dose Additional Digestive/
molecular weight Animal  %CG (g/kg bw/day) Duration Route exposure systemic  Histopathologic changes Neoplastic changes Reference
16. Degradeda,d Rat 10 2 weeks Diet 1,2-DMH weekly Increase in tumors (64)
injections for 15  of small intestine
weeks (10 mg/kg bw)  (50% vs. 25%) and
with DCG vs. DMH  colon (60% vs. 45%)
alone with CG than occurred
with DMH alone.
17. Degraded, Rat 10 15 < 63 days Diet Germ-free vs. Erosions; aggregates of foamy  Squamous metaplasia (65)
(20,000–40,000)a,b,c,g conventional gut  metachromatic macrophages from anorectal junction
ﬂora in submucosa and lamina to distal colon.
propria.
18. Degraded Guinea pig 3 3 weeks Drink Diarrhea after 7 No cecal or colonic (66)
κ, λ, ι days. Moribund lesions seen.
after 9 days of
ιDCG.
19. Degraded Rat 10 2, 6, 9  Diet Basal diet after CG in mucosa 100% incidence of  (67)
(20,000–40,000)a,b,e months DCG exposure and RE system. colorectal squamous
sacriﬁced at  metaplasia that progressed
18 months after DCG intake discontinued.
20. Degradedc Guinea 5 ≤ 28 days Drink Cecal lesions after 24 hr;  (68)
pig conﬂuent ulcerations after
7 days. Macrophage inﬁltration.
21. Undegraded, Rat, 0.5, 2.5, 5 0.36, 2, 4 Lifetime Diet Diarrhea in some No difference in Increased incidence (69)
(800,000) hamster ulcerations from control. of benign mammary
(largely κ) tumors and testicular
neoplasms (at 2.5% 
level) in rats only.
22. Degradeda,b,c,g Rat 10 1 day to 12  Diet Superﬁcial erosions Squamous metaplasia (70)
weeks, some  at anorectal junction of rectal mucosa at 2 weeks;
sacriﬁced  at 24 hr; at 2 weeks,  extended after no
at 27 weeks more proximal erosions. longer being fed CG.
23. Degradedc Guinea  2 2 weeks Drink Loose stools by  100% with colonic ulcerations; (34)
pig 2 weeks 75% had over 200 ulcers.
24. Degradedc Guinea  5 21 days 17/22 died  All had mucosal ulcerations  (71)
pig by day 21  from cecum to rectum by day 14.
25. Degraded Rat 10, 5, 1 ≤ 24 months Diet Squamous cell  (72)
(20,000–40,000)a,b 5 15 months drink carcinomas,
1 or 5 15 months Stomach tube adenocarcinomas,
adenomas. 32% and
fed 10% diet had tumors. 
100% incidence of metaplasia 
with 5% drink.
26.Undegraded λa,d Rat 15 ≤ 40 weeks Diet NMU 2 mg twice 100% had tumors with (73)
weekly rectally AOM and UCG vs. 57%
for 3 weeks; with AOM alone.
AOM (8 mg/kg bw) 100% had tumors with
SC for 10 weeks; NMU and UCG vs. 69% 
UCG with NMU, with NMU alone.
UCG with AOM 0 tumors in control, 7% 
tumors with UCG alone.
UCG with AOM had 10-fold
increase in number of 
tumors per rat.
27. ι, Rat 0.5 9 months Gavage Av MW of CG in liver was  (74)
(8,700–145,000)e,f at 10,000; all CG in feces
Undegraded κ/λ, Rat 5 13 weeks  Diet had MW < 100,000.
(186,000–214,000)
ι,  Guinea pig 2 7–10 weeks Diet
(5,000–145,000)
ι, Guinea pig 1 2–3 weeks Drink
(5,000–145,000)
κ, Guinea pig 1 2–3 weeks Drink
8,500–275,000
λ, Guinea pig 1 2–3 weeks Drink
(8,500–275,000)
Undegraded κ/λ, Rhesus  0.05, 0.2, 0.5 Stomach tube 
(185,000) monkey 
ι 0.2 Stomach tube
Continued, next page 78–80,82,83,86–93). Ulcerations arose in
association with exposure to either degraded
or undegraded carrageenan. Lesions
occurred initially in the cecum of guinea
pigs and rabbits, but could be induced in
more distal parts of the colon of the guinea
pig, as in an experiment in which car-
rageenan was introduced directly into the
colon after ileotransversostomy (63). In rats,
the ulcerative lesions appeared initially in dis-
tal colon and rectum (8). Undegraded and
degraded carrageenan have been associated
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Table 3. Continued
Experiment
Type of Effects
carrageenan, Dose Additional Digestive/
molecular weight Animal  %CG (g/kg bw/day) Duration Route exposure systemic  Histopathologic changes Neoplastic changes Reference
28.κc Guinea  Cecal ulceration not seen with  (75)
(314,000) pig 1 2 weeks Drink κ or λ; ι fractions of MW 21,000–
(51,500) 2 weeks Drink  107,000 led to ulcerations of cecum,
(8,500) 2 weeks  Drink crypt abscesses, and epithelial
λ, thinning. ι fractions absorbed and
(275,000) 2 weeks Drink seen in vacuolated macrophages.
(74,800) 2 weeks Drink Intense lysosomal enzymatic activity 
(20,800) 2 weeks Drink in macrophages of lamina propria.
ι,
(145,000) 2 weeks Drink
10 weeks Diet
(107,000) 2 weeks Drink
10 weeks Diet
(88,000) 2 weeks Drink
(39,000) 2 weeks Drink
10 weeks Diet
(21,000) 2 weeks Drink
10 weeks Diet
(8,700) 2 weeks Drink
10 weeks Diet 
(5,000) 2 weeks Drink
29. Degraded  Rhesus 2 10 weeks  Drink Macrophages given DCG had (76)
ι (C16), monkey ﬁbrillar material and vacuolations.
(20,000)
Undegraded Rhesus 1 10 weeks Drink Vacuolations seen with UCG.
κλ mixture, monkey
(800,000)
30. Degraded Rat 5 ≤ 30 weeks Drink, 1,2-DMH Watery, bloody  Distal rectum transformed DMH with DCG- (77)
(ι, C16), 7.5 g, then 5 g diet (20 mg/kg) stools to stratiﬁed squamous by induced proliferation 
(10,000–30,000)a,d SC/wk DMH with DCG. of deep glandular areas;
more poorly differentiated
adenocarcinomas; more
frequently found tumors 
of ascending and transverse 
colon with DMH and DCG.
31. Degradedc,e Rat 0.2, 0.5, 5 ≤ 12 weeks Drink Severe diarrhea  DCG contained within  (78)
in 3 days macrophages of spleen,
with 5% liver, kidney, small and
large intestine; cecal 
Guinea pig 0.25, 0.5 ≤ 4 weeks Drink Diarrhea and colonic ulcerations
at 4 weeks.
32. Degraded Guinea pig 2, 0.2, 0.02 12 months, Drink 2% CG in water, but not in  (79)
(ι, C16)c 10 months milk, led to cecal ulceration
Guinea pig 2 3 months In milk in guinea pig. DCG in macro-
phages of submucosal layer in
guinea pigs, rats, and monkeys.
Rat 5 3 months Drink No cecal ulceration seen in 
Monkey 2 10 weeks Drink rats or monkeys.
33. Degradedc Guinea pig 2, 5 1.7–3.3 30–44 days Drink Trimethoprim/ Blood in stools Cecum and distal colon had (80)
Sulfame- ulcerations, crypt abscesses;
thoxazole enlarged cecal or colonic
lymph nodes; more extensive
ulceration with 5%; fewer 
lesions with antibiotic. 
Inﬁltration of foamy macrophages.
34. Undegraded κ, Pig 0.05, 0.2, 0.5 83 days Jelly  Focal irregularities without  (81)
(200,000) ulcerations; thickened lamina 
propria; macrophage inﬁltration.
35. Degraded Rhesus 0.5–2 0.7, 1.4, 2.9 7–14 weeks, Drink Diarrhea, Ulcerations of colon; hypertrophy  (82)
(C16, ι),c monkey then recovery  hemorrhage of mesenteric lymph nodes and
(20,000) for 20–24 weeks granulomas; multiple crypt
for some abscesses; dose effect present.
before 
sacriﬁced
Undegraded Rhesus 1  1.3  7–14 weeks, Drink Without colonic changes.
(largely κ), monkey then 11 weeks
(800,000) recovery
1–3 0.05–1.25 ≤ 12 weeks, Tube
after recovery 
Continued next pagewith epithelial cell loss and erosions in rats
(51,65,70,87,93). 
Watt et al. (34) ﬁrst observed ulcerations
in response to carrageenan exposure in
animal models more than three decades ago.
They noted that 100% of guinea pigs given
2% degraded carrageenan as liquid for
20–30 days had colonic ulcerations and that
75% of the animals > 200 ulcers (34). When
guinea pigs were given 1% undegraded car-
rageenan as liquid for 20–30 days, 80%
developed colonic ulcerations (92). The
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Table 3. Continued
Experiment
Type of Effects
carrageenan, Dose Additional Digestive/
molecular weight Animal  %CG (g/kg bw/day) Duration Route exposure systemic  Histopathologic changes Neoplastic changes Reference
36. Undegraded Guinea pig 5 1–45 days Diet Neomycin  Diarrhea,  Multiple pinpoint cecal and colonic (83)
Rabbit 5 Diet (0.1%) added hemorrhage  ulcerations after 3–5 weeks in 
Degradedc Guinea pig 1, 2, 5 1–45 days Drink guinea pig and rabbit. Macrophages 
Rabbit 2 Drink increased; inclusions and vacuoles 
in macrophages; granulomas seen. 
Neomycin did not affect incidence
of ulcers or time of onset. 
Degraded Humans 5-g dose 10 days Diet Patients had colon malignancy
with colectomy planned to follow
CG exposure, no ulcerations seen.
Ferret 1.5 28 days Tube No lesions seen.
Squirrel monkey 1.5 28 days Tube No lesions seen.
Rabbit, 1.5 28 days Tube 
mouse No lesions seen.
Rat  1 56 days Drink Sl diarrhea
Rat 5 Diarrhea
Undegraded Rat  5 56 days Diet Sl diarrhea
Hamster 5 6  months Diet Diarrhea
37. Degraded Rat 5 6–10 ≥ 25 weeks Drink FOB+ by  Metachromatic material Adenomatous  (84)
(c16, ι), 0.5–5.0  1–15 months Tube 3–7 days with  thought to be CG found in and hyperplastic
(20,000–30,000)a,b,e > 5 g/kg/day; RE cells of liver, spleen, polyps in one rat.
gross blood lymph nodes, macrophages  Squamous metaplasia
by 2–3 weeks of lamina propria and of anorectal region 
submucosa. No cecal lesions. and distal colon.
38. Undegraded Rhesus 1 7–12 weeks Drink No changes in liver. (85)
(κ:λ = 70:30), monkey
(800,000)e
Degraded Rhesus 0.5, 1, 2  7–12 weeks Drink Membrane-bound vacuoles 
(C16, ι), monkey with ﬁbrillar material in RE 
(20,000–30,000)e cells of liver.
39. Degradedc Guinea 5 ≤ 2 g 20–45 days Drink FOB+, Multiple ulcers in cecum, colon, (86)
pig diarrhea and rectum in 100% of animals 
by 1 week by day 30.
40. Degradeda,b,c,g Rat 5 6 months Drink Ulceration of cecum in 4/12, (87)
associated with stricture;
marked glandular hyperplasia
at ulcer margins.
41. Undegradedc Guinea  5 2–4 weeks Diet Ulceration of mucosa as  (88)
pig consequence of macrophage 
Degradedc Guinea  1 2–4 weeks Drink accumulation in lamina propria, 
pig then submucosa.
42. Degradeda,b,c Rabbit 0.1, 1, 5 0.07, 0.8, 6–12 weeks Drink  Diarrhea,  Ulceration of colon in Hyperplastic (89,90)
1.4 blood by 100% of those fed 1%; mucosal changes,
day 7, 60% of those fed 0.1%. polypoidal lesions.
weight loss
43. Degradedc Guinea 4–5  Drink Mucosal erosions in cecum,  (91)
pig rarely into colon in guinea pig;
Degraded Rat ≤ 16.5 Drink without erosion in rat or mouse.
Degraded, Rat, 0.07–4 28  days– Tube 
Undegraded mouse 6 months
44. Undegraded Guinea pig 1 ≤ 1.5 20–30 days Drink FOB+ Multiple ulcerations of cecum;  (92)
80% had ulcerations. Crypt
abscesses present; macrophages,
with metachromatic material.
Degraded Guinea  ≤ 5 ≤ 2 20–30 days Drink Diarrhea by  100% had ulcerations; ulceration 
pig 10 days,  extended into distal colon
FOB+ and rectum.
45. Degraded Guinea pig 0.1–5 30 days– Drink Weight loss in Hemorrhagic and ulcerative (93)
Rabbit 1 year Drink guinea pig and lesions in cecum, colon, or
Rat Drink rabbit, not rat or rectum in all four species;
Mouse Drink mouse. Blood crypt abscesses present.
and mucous in
stool.
Abbreviations: AOM, azoxymethane; bw, body weight, CG,carrageenan; DCG, degraded carrageenan; DMH, dimethylhydrazine; FOB, fecal occult blood; ip, intraperitoneal; NMU, nitro-
somethylurea; PEG, polyethylene glycol; SC, subcutaneous; Sl, slight; tube, gastric intubation; UCG, undegraded carrageenan. 
aStudies are associated with neoplastic changes, unlike studies predominantly demonstrating intestinal ulcerations. bIncreased proliferation or neoplasm and carrageenan alone.
cUlcerations and carrageenan alone. dNeoplasms in which carrageenan promoted carcinogenesis. eStudies with uptake to lymph node or other site. fStudy demonstrating breakdown to
lower molecular weight. gStudies demonstrating ulcerations in rat using degraded carrageenan. lesions were routinely produced with car-
rageenan concentrations of 0.1–1%, which is
similar to the concentration in a variety of
food products (7,12–14).
Grasso et al. (83) demonstrated pinpoint
cecal and colonic ulcerations in guinea pigs
and rabbits given 5% undegraded, as well as
degraded, carrageenan in the diet for 3–5
weeks. Lesions were not observed in ferrets
and squirrel monkeys given degraded car-
rageenan by gastric intubation (83). Other
investigators have also observed ulcerations
after exposure to either degraded or unde-
graded carrageenan (75,88). Engster and
Abraham (75) observed ulceration of cecum
in guinea pigs given ι-carrageenan of molec-
ular weight 21,000–107,000, demonstrating
ulcerations were also caused by higher mole-
cular weight carrageenan. Cecal ulcerations
were not found with exposures to κ or λ car-
rageenan of molecular weight varying from
8,500–314,000. 
Investigators have noted that car-
rageenan-induced ulcerations of the colon
are dose dependent and related to duration
of exposure (52,53,67,68,70,89,90).
Kitsukawa et al. (52) observed small epithe-
lial ulcerations in guinea pigs who received
carrageenan in their drinking fluid at two
days. Olsen and Paulsen (68) observed cecal
lesions after 24 hr and conﬂuent ulcerations
after 7 days in guinea pigs that ingested a
5% carrageenan solution. In rats, superﬁcial
erosions were observed at the anorectal junc-
tion at 24 hr after 10% dietary carrageenan
(70); these extended more proximally over
time. In 5 days of feeding with a 5% car-
rageenan solution, Jensen et al. (62)
observed as many as 111 ulcerations/cm2
over the mucosal surface of the cecum in the
guinea pig.
Benitz et al. (82) observed a dose effect
when degraded carrageenan was given at
concentrations of 0.5–2% in drinking ﬂuid
to rhesus monkeys for 7–14 weeks. Watt
and Marcus (89) observed that in rabbits
given 0.1% degraded carrageenan as drink-
ing fluid, 60% of the animals developed
ulcerations, whereas 100% of those given
1% carrageenan had ulcerations when
exposed for 6–12 weeks.
Resemblance to ulcerative colitis. Several
investigators have noted the resemblance
between the ulcerative lesions and accompa-
nying inﬂammatory changes induced by car-
rageenan and the clinical spectrum of
ulcerative colitis (56,94–99). Since the devel-
opment of the carrageenan-induced model of
ulcerative disease of the colon in 1969, car-
rageenan exposure has been used to model
ulcerative colitis and to test for response to
different treatments (52,62,100,101). 
Clinical features in the experimental ani-
mals exposed to carrageenan have included
weight loss, anemia, diarrhea, mucous in
stools, and visible or occult blood in stools.
The absence of small intestinal lesions and
the lack of remission and exacerbation are
also characteristic features of the carrageenan
model (99,102).
Onderdonk (94) discussed the similarity
between the carrageenan model of colitis and
ulcerative colitis in humans and considered
whether animal models for inflammatory
bowel disease were also models for intestinal
cancer because of the increased risk of colon
cancer in individuals with ulcerative colitis. He
reviewed the findings from carrageenan-
treated animals, including loss of haustral
folds, mucosal granularity, crypt abscesses,
lymphocytic inﬁltration, capillary congestion,
pseudopolyps, and strictures. Other observa-
tions have demonstrated an apparent sequence
from colitis to squamous metaplasia and then
to tumors of the colorectum (67,72,102).
Atypical epithelial hyperplasia in the vicinity
of carrageenan-induced ulcerations resembled
findings from human ulcerative colitis that
provide a link to intestinal neoplasia (86,98). 
Proposed mechanism of development of
lesions. A common feature observed in the
animal models of ulceration in association
with carrageenan exposure is macrophage
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Figure 1. Carrageenan and promotion of neo-
plasms. No tumors were found in the control ani-
mals. With AOM and undegraded carrageenan,
there was a 10-fold increase in the number of
tumors per rat. See text for exposure regimens
(73). 1,2-Dimethylhydrazine (1,2-DMH) alone
caused neoplams in 40% of animals tested; with
addition of undegraded carrageenan, 75% of
exposed animals had tumors that were larger and
occurred more frequently proximal (57). The com-
bination of 1,2-DMH and degraded carrageenan
was associated with an increase in small intesti-
nal tumors from 20% to 50% of exposed animals
and with an increase from 45% to 60% in large
intestinal tumors (64). 
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Table 5. Experimental evidence for presence of low molecular weight carrageenan in food-grade car-
rageenan and production of low molecular weight carrageenan by acid hydrolysis or by bacteria.
(9,10,36–40).
Degraded carrageenan in food-grade carrageenan
25% of total carrageenans in eight food-grade κ-carrageenans had MW < 100,000
9% of total carrageenan in eight food-grade κ-carrageenans had MW < 50,000
Production of degraded carrageenan by acid hydrolysis of food-grade carrageenan
In simulated gastric ﬂuid (including pepsin and HCL), κ-carrageenan at pH 1.2, 37°C
for 1 hr leads to 17% degraded carrageenan with MW < 20,000
for 2 hr leads to 25% with MW < 20,000
In simulated gastric ﬂuid (including pepsin and HCL), κ-carrageenan at pH 1.9, 37°C
for 1 hr leads to 8% with MW < 20,000
for 2 hr leads to 10% with MW < 20,000
κ-carrageenan in solution at pH 1.0, 37°C, for 6 hours, leads to 25% with MW < 20,000
ι-carrageenan in solution at pH 1.0, 37°C, for 6 hours, leads to 10% with MW < 25,000
Hydrolysis of carrageenan by bacterial carrageenases
κ- and ι-carrageenase from cell-free supernatant from culture of Cytophaga genus
κ-carrageenase isolated from cell-free medium of cultured Pseudomonas carrageenovora
λ-carrageenase from cell-free medium of Pseudomonas carrageenovora cultures 
MW, molecular weight.
Table 4. Proposed mechanism for effects of carrageenan (9,10,35,67,72,75,76,79,84–86,88,98,102,105,
107–110,114,115).
Site Effect
Intestinal lumen Ingested carrageenan can undergo acid hydrolysis in stomach,
possible breakdown by intestinal bacteria.
Intestinal epithelial cells Take up degraded carrageenan, as indicated by metachromatic staining
from cecum to rectum. Vacuoles observed to contain metachromatic
material. Epithelial cells may undergo lysis from effect of lysosomal 
disruption producing erosions.
Inﬂammatory inﬁltrate  Polymorphonuclear cells and macrophages inﬁltrate to site of intestinal
inﬂammation. Macrophages have metachromatic staining associated
with uptake of degraded carrageenan. Lysosomal vacuolation occurs
as well as lysosomal disruption with release of intracellular 
enzymes from macrophage destruction, leading to intestinal 
ulcerations. Process of chronic inﬂammation, as 
with ulcerative colitis.
Macrophage circulation Macrophages may circulate and may lead to extraintestinal effects
related to carrageenan. infiltration (35,56,63,65,68,75,76,78–81,
83,84,88,92,102–104). Fibrillar material and
metachromatic staining of the macrophages
were observed. Notably, the macrophage
lysosomes appeared to take up the fibrillar
material and to become distorted and vacuo-
lated. It appeared that colonic ulcerations
developed as a result of macrophage lysoso-
mal disruption, with release of intracellular
enzymes, subsequent macrophage lysis, and
release of intracellular contents that provoked
epithelial ulceration (75,76,79,84,85,88,
105,106). In the rhesus monkey, Mankes
and Abraham (76) observed vacuolated
macrophages with ﬁbrillar material when the
animals were given undegraded carrageenan
of molecular weight 800,000 as a 1% solu-
tion in their drinking fluid, demonstrating
the occurrence of these changes after expo-
sure to undegraded as well as to degraded
carrageenan.
In an effort to clarify further the precise
pathogenic changes that occurred, Marcus et
al. (35) evaluated pre-ulcerative lesions after
exposure of guinea pigs to degraded car-
rageenan for only 2–3 days. The animals
received 3% drinking solution of car-
rageenan, with an average daily carrageenan
intake of 5.8 g/kg. Early focal lesions were
observed macroscopically in the cecum in
only one animal with this brief exposure.
However, in all test animals, a diffuse cellular
infiltrate, with macrophages and polymor-
phonuclear leukocytes, was apparent micro-
scopically. Inflammatory changes in the
cecum and ascending colon were present in
all animals, and in the distal colon and rec-
tum in three of four animals. Metachromatic
staining material was noted in the lamina
propria of the colon and surface epithelial
cells from cecum to rectum, as well as in
colonic macrophages. The surface epithelial
cells and the macrophages contained vac-
uoles ﬁlled with the metachromatic material,
which was not found in the controls and not
seen in more advanced lesions in previous
studies. These early lesions suggested that
the presence of degraded carrageenan within
surface epithelial cells might be associated
with the subsequent breakdown of the
mucosa and to ulceration by a direct toxic
effect on the epithelial cells (35). 
Hence, a model of mechanical cellular
destruction by disruption of lysosomes from
carrageenan exposure arises from review of
the experimental studies in animals. The
observed changes in the lysosomes resemble
the characteristic changes observed in some
lysosomal storage diseases, in which there is
accumulation of sulfated metabolites that
cannot be processed further due to sulfatase
enzyme deﬁciency (107–110). Table 4 pre-
sents a proposed mechanism of the effects of
carrageenan. 
Possible role of intestinal bacteria. The
relationship between the intestinal
microflora and the biologic activity of car-
rageenan has been reviewed (111,112).
Investigators have examined the impact of
antibiotics and alteration of the resident
microbial flora on the activity of car-
rageenan. Grasso et al. (83) studied the
impact of neomycin treatment on the devel-
opment of ulcerations by carrageenan.
Pretreatment against coliforms failed to
attenuate the course of carrageenan-associ-
ated ulcerations (80,83). Pretreatment with
metronidazole was effective in preventing
carrageenan-induced colitis in another exper-
iment, although there was no benefit in
established colitis (71). Aminoglycosides
administered after carrageenan exposure
were associated with reduced mortality, but
not with reduction in the number of colonic
ulcerations (94). Hirono et al. (65)  found
increased ulcerations and squamous metapla-
sia from the anorectal junction to the distal
colon in germ-free rats fed 10% carrageenan
for less than 63 days.
Additional considerations about the
mechanism of action of carrageenan involved
the role of production of hydrogen sulﬁde gas
from metabolism of carrageenan in the diges-
tive tract. Because carrageenan is heavily sul-
fated (up to 40% by weight), bacterial
sulfatases and sulfate reductases can produce
hydrogen sulfide gas or HS– from car-
rageenan. Carrageenan, as well as other sul-
fated polysaccharides, has been shown to
stimulate H2S production from fecal slurries
(113). Sulfide has been implicated in the
development of ulcerative colitis, perhaps
attributable to interference with butyrate oxi-
dation by colonic epithelial cells (114,115).
Butyrate has been shown to induce intestinal
cellular differentiation, suppress intestinal cell
growth, and decrease expression of c-myc,
among other functions in colonic epithelial
cells (116–118).
No fermentation of carrageenan was
reported after testing with 14 strains of
intestinal bacteria. The increase in sulfide
production observed arising from incubation
of λ-carrageenan with colonic bacteria
demonstrates that intestinal metabolism of
carrageenan does occur. However, data per-
taining to breakdown of carrageenan by fecal
organisms are limited (112,113).
Extraintestinal manifestations of car-
rageenan exposure. Trace amounts of un-
degraded carrageenan have been reported to
cross the intestinal barrier, with accumula-
tion of label in intestinal lymph nodes
(61,74). Several investigators have noted
uptake of carrageenan by intestinal
macrophages with subsequent migration of
these macrophages to lymph nodes, spleen,
and liver (61,67,74,78,82,84,85).
In association with carrageenan-induced
intestinal ulcerations, Delahunty et al. (56)
observed an increased permeability to large
molecules, such as [3H]PEG (polyethylene
glycol)-900. This ﬁnding suggested that the
intestinal changes induced by carrageenan
may be a factor in subsequent absorption of
carrageenan or other large molecules. 
Other experimental data. Because it can
induce acute inﬂammation, carrageenan has
been widely used in experimental models of
inflammation to assess activity of anti-
inﬂammatory drugs and to study mediators
of inflammation (4,61,106,119,120).
Injected into an experimental site, such as
the plantar surface of a rat’s paw, pleural cav-
ity, or subcutaneous air bleb, carrageenan
induces an inflammatory response, with
edema, migration of inﬂammatory cells, pre-
dominantly polymorphonuclear leukocytes,
and possibly granuloma formation (61,120).
Undegraded carrageenans in vitro can inhibit
binding of basic fibroblast growth factor
(bFGF), transforming growth factor β-1,
and platelet-derived growth factor but not
insulin-like growth factor-1 or transforming
growth factor-α (121). 
Macrophage injury and destruction
caused by carrageenan may be a factor in the
reduced cytotoxic lymphocytic response
associated with carrageenan exposure in vivo
(122). In addition to depression of cell-
mediated immunity, impairment of comple-
ment activity and of humoral responses have
been reported. Prolongation of graft survival
and potentiation of tumor growth have been
attributed to the cytopathic effect on
macrophages (96,123). Because of its effect
on T-cells, carrageenan has been studied for
its impact on viral infections with herpes
simplex virus types 1 and 2 (124) and HIV-
1 (125,126), as well as infections with
Chlamydia trachomatis (127). 
In experimental systems, undegraded car-
rageenan has produced destruction of several
different cell types in addition to macro-
phages, including small intestine epithelial
cell monolayers (54), androgen-dependent
malignant prostatic cells (128), bFGF-depen-
dent endothelial cell line (128), rat mammary
adenocarcinoma 13762 MAT cells (129),
and human mammary myoepithelial cells
(130). Lysosomal inclusions and vacuolation
have been observed in macrophages, intesti-
nal epithelial cells, and myoepithelial cells
exposed to carrageenan (79,85,131). 
Injections of carrageenan were noted to
induce sarcomas, as well as mammary tumors
in animal models, in an early study (132). In
other experiments, mammary and testicular
tumors have been observed (69,133).
Carrageenan has also been noted to have anti-
coagulant activity, and large systemic doses
have been fatal through nephrotoxicity (4).
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Degraded Carrageenan from 
Undegraded Carrageenan
Gastrointestinal metabolism of carrageenan to
form smaller molecular weight components
has been observed by several investigators,
who reported that carrageenan of high molec-
ular weight changed during intestinal passage,
compatible with hydrolysis yielding lower
molecular weight components (9,10,74,75).
Under conditions such as might occur in
digestion, 17% of food-grade carrageenan
degraded to molecular weight < 20,000 in 1
hr at pH 1.2 at 37°C. At pH 1.9 for 2 hr at
37°C, 10% of the carrageenan had molecu-
lar weight less than 20,000 (9). These data
suggest that substantial fractions of lower
molecular weight carrageenan are likely to
arise during normal digestion. 
Table 5 presents data with regard to con-
tamination of food-grade carrageenan by
lower molecular weight carrageenan.
Twenty-ﬁve percent of total carrageenans in
eight food-grade carrageenans were found to
have molecular weight < 100,000, with 9%
having molecular weight < 50,000 (9). In
addition, several bacteria have been identi-
fied that are able to hydrolyze carrageenan
into smaller products, including tetracarra-
biose. These bacteria, including Cytophaga
species and Pseudomonas carrageenovora, are
of marine origin; it is unknown whether the
human microbial flora can perform similar
hydrolysis reactions (36–40,134). 
Extent of Human Exposure to
Carrageenan
Indirect evidence relating exposure to car-
rageenan and the occurrence of ulcerative colitis
and intestinal neoplasms consists of the similar
geographic distribution between higher con-
sumption of carrageenan and higher incidence
of inﬂammatory bowel disease and colorectal
cancer. Ulcerative colitis is more common in
North America, the United Kingdom, and
Scandinavia, and less common in Central and
Southern Europe, Asia, and Africa (135). This
incidence distribution is similar to distributions
for colorectal malignancy and for carrageenan
consumption, providing some ecologic evi-
dence to support a potential etiologic role of
carrageenan in human disease (46,136). 
The reported TD50 (tumorigenic dose
50% = the dose rate, in milligrams per kilo-
gram body weight per day, which will halve
the probability of remaining tumorless over
the life span of the exposed animal) by the
Carcinogenic Potency Database for degraded
carrageenan is 2,310 mg/kg body weight/day,
based on rodent experiments (137,138). This
extrapolates to 138.6 grams for a 60-kg indi-
vidual. If the total carrageenan intake per
person in the United States is about 100 mg
a day (43), about 9 mg of carrageenan with
molecular weight < 50,000 is likely to be
ingested through contamination of food-
grade carrageenan by degraded carrageenan,
and at least 8 mg with molecular weight <
20,000 is likely to arise during normal diges-
tion (simulated by exposure to pH 1.9 with
pepsin for 1 hr at 37°C). This suggests an
average intake of about 10 mg/day of
degraded carrageenan for an individual older
than 2 years of age in the United States.
An important issue is whether 10 mg/day
degraded carrageenan is safe to ingest. By the
Delaney clause, no carcinogen should be per-
mitted in food. The Food Quality Protection
Act (FQPA) established a usage level for neg-
ligible risk associated with pesticide residue in
food at 1 ppm (139,140). Applying this stan-
dard to the extrapolated TD50 for degraded
carrageenan for a 60-kg person, the antici-
pated average intake of 10 mg/day is 70-fold
greater than this standard (138.6 g/106/day).
These calculations do not take into consider-
ation possible exposure to furcellaran (molec-
ular weight 20,000–80,000), or the wide
range of possible intakes of carrageenan.
Conclusion
Inflammatory bowel disease and colorectal
malignancy represent major sources of mor-
bidity and mortality in the United States. A
possible factor in the etiology of these
pathologies is exposure to carrageenan. 
Several investigators have expressed their
concerns about the use of undegraded car-
rageenan in food products (6–10), yet no
legislative protection to restrict incorpora-
tion of low molecular weight fractions has
been enacted. In fact, there has been no sub-
stantive review by the Food and Drug
Administration of carrageenan since the
studies undertaken more than two decades
ago. However, there has been increased evi-
dence regarding the cancer-promoting activ-
ity of undegraded carrageenan and further
conﬁrmation of the carcinogenic potential of
degraded carrageenan. 
Evidence for the role in carcinogenesis of
carrageenan appears to support a non-
genotoxic model based on direct toxic effects,
for carrageenan has been nonmutagenic in
Salmonella mutagenicity testing and nongeno-
toxic by DNA repair tests (60,102). A model
of cellular destruction—from disruption of
lysosomes by accumulation of carrageenan
by-products or by interference with normal
cellular oxidation–reduction processes from
sulfate metabolites—emerges from review of
the experimental studies. The impact of sulfa-
tases, of either bacterial or human origin, on
the metabolism of carrageenan requires fur-
ther investigation. By interference with the
normal intracellular feedback mechanisms
associated with arylsulfatase activity, including
steroid sulfatase, the highly sulfated car-
rageenan may have an impact on the availabil-
ity of active, unsulfated hormones, such as
dehydroepiandrosterone, derived from dehy-
droepiandrosterone-sulfate, and estrone-1,
derived from estrone-1 sulfate.
Genetic characteristics that affect sulfa-
tase and hydrolysis reactions as well as the
individual intestinal microflora may influ-
ence how carrageenan is metabolized and
how its effects are manifested. These factors
may determine how carrageenan is metabo-
lized differently by different individuals, but
these characteristics may not be accessible to
manipulation. A basic factor that can be
controlled is the intake of carrageenan,
which is amenable to dietary modiﬁcation or
food additive regulation.
Although carrageenan is widely used as a
food additive for its texture-enhancing
properties, other gums, some of which are
used in combination with carrageenan, such
as locust bean gum, gum arabic, alginate,
guar gum, or xanthan gum, potentially can
be used alone or in different combinations
as substitutes for carrageenan (41,46).
Alternatively, higher fat composition can
lead to changes in food properties that may
compensate for exclusion of carrageenan.
Other hydrocolloids that are used as stabi-
lizers and thickeners have not been associ-
ated with harmful gastrointestinal effects,
and it is reasonable to expect that they could
replace carrageenan in many food products.
Although the dietary ﬁbers pectin and psyl-
lium affect intestinal motility, ulcerations or
neoplasms have not been induced with
either these or the other water-soluble poly-
mers used as food additives. In contrast,
other highly sulfated polysaccharides, amy-
lopectin sulfate and dextran sulfate sodium,
have induced ulcerations and neoplasia, sug-
gesting that the degree of sulfation and poly-
saccharide molecular weight may be critical
for induction of the observed effects (102). 
The major pieces of evidence that sup-
port an argument to reconsider the advisabil-
ity of use of carrageenan as a GRAS food
additive are: 
• Degraded carrageenan is a known carcino-
gen in animal models 
• Undegraded carrageenan is a known co-car-
cinogen in animal models of carcinogenesis 
• In animal models, both degraded and
undegraded carrageenan have been associ-
ated with development of intestinal ulcera-
tions that resemble ulcerative colitis 
• Hydrolysis such as may occur by exposure
to gastric acid in the human stomach
can lead to the depolymerization of
undegraded carrageenan and the availabil-
ity of degraded carrageenan 
• Food-grade carrageenan may be contami-
nated with low molecular weight, degraded
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processing 
• The use of a viscosity measurement to
characterize a carrageenan sample is insufﬁ-
cient because the presence of a small num-
ber of large molecules (and undegraded
carrageenan may have molecular weight in
the millions) may obscure a signiﬁcant low
molecular weight fraction. 
The potential role of carrageenan in the
development of gastrointestinal malignancy
and inflammatory bowel disease requires
careful reconsideration of the advisability of
its continued use as a food additive.
REFERENCES AND NOTES
1. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L,
Edwards BK. SEER Cancer Statistics Review 1973–1996.
Bethesda, MD:National Cancer Institute, 1999. 
2. Schottenfeld D, Winawer SJ. Cancers of the large intes-
tine. In: Cancer Epidemiology and Prevention (Schottenfeld
D, Fraumeni J, eds). 2nd ed. New York:Oxford University
Press, 1996;813–840.
3. Schatzkin A. Available: http://rex.nci.nih.gov/
NCI_Pub_Interface/raterisk/risks129.html [cited 6
October 2000]. 
4. IARC. IARC Working Group on the Evaluation of the
Carcinogenic Risk of Chemicals to Humans.
Carrageenan. IARC Monogr Eval Carcinog Risk Hum
31:79–94 (1983).
5. National Research Council. Carcinogens and Anti-car-
cinogens in the Human Diet. Washington, DC:National
Academy Press, 1996;398.
6. Marcus R, Watt J. Danger of carrageenan in foods and
[Letter]. Lancet 1:338 (1981). 
7. Marcus R, Watt J. Potential hazards of carrageenan
[Letter]. Lancet 1:602–603 (1980).
8. Marcus R. Harmful effects of carrageenan fed to ani-
mals. Cancer Detect Prev 4:129–134 (1981).
9 Ekstrom L-G. Molecular weight distribution and the
behavior of kappa-carrageenan on hydrolysis. Carbohydr
Res 135:283–289 (1985).
10. Ekstrom L-G, Kuivinen J, Johansson G. Molecular weight
distribution and hydrolysis behavior of carrageenans.
Carbohydr Res 116:89–94 (1983).
11. Yu G, Ioanoviciu AS, Sikkander SA, Thanawiroon C,
Toida T, Tobacman J, Linhardt RJ. Unpublished data. 
12. Klose RE, Glicksman M. Gums. In: Handbook of Food
Additives (Furia TE, ed). Cleveland, OH:The Chemical
Rubber Co., 1968;313–375.
13. Towle GA. Carrageenan. In: Industrial Gums:
Polysaccharides and Their Derivatives (Whistler RL, ed).
New York:Academic Press, Inc., 1973;84–109. 
14. Moirano AL. Sulfated seaweed polysaccharides. In: Food
Colloids (Graham HD, ed). Westport, CT:AVI Publishing
Co., 1977;347–381.
15. Daniel JR, Voragen ACJ, Pilnik W. Starch and other poly-
saccharides. In: Ullmann’s Encyclopedia of Industrial
Chemistry, Vol A 25 (Elvers B, Hawkins S, Russey W,
eds). New York:VCH Verlagsgesellschaft, 1994;21–62.
16. Substances that are generally recognized as safe. Fed
Reg 21:9368–9370. 
17. Food and Drugs: Food Additives. 21 C.F.R.
121.101,121.1063,121.1066,121.1067,121.1069, 1969. 
18. Proposed Revision of Food Additive Regulations and
Deletion of Chondrus Extract (Carrageenin) from Generally
Regarded as Safe (GRAS) List. 37 Fed Reg 15434.
19. Informatics, Inc. Carrageenan. Arlington, VA:National
Technical and Information Service, 1972;1–68.
20. Nicklin S, Miller K. Intestinal uptake and immunological
effects of carrageenan—current concepts. Food Addit
Contam 6(4):425–436 (1989).
21. Food and Nutrition Board, National Research Council.
Estimating Distribution of Daily Intakes of Chondrus
Extract (Carrageenan): Committee on GRAS List Survey–
Phase III. Appendix C. Washington, DC:National
Academy of Sciences, 1976;1–7. 
22. Stanicoff DJ, Renn DW. Physiological effects of car-
rageenan. In: ACS Symposium Series (15): Physiological
Effects of Food Carbohydrates (Gould RF, ed). Washington,
DC:American Chemical Society, 1975; 282–295.
23. Pintauro SJ, Gilbert SW. The effects of carrageenan on
drug-metabolizing enzyme system activities in the
guinea-pig. Food Chem Toxicol 28:807–811 (1990).
24. Carrageenan, Salts of Carrageenan and Chondrus
Extract (Carrageenin); Withdrawal of Proposal and
Termination of Rulemaking Proceeding. Fed Reg
44:40343–40345.
25. International Food Additives Council and FMC Corporation-
Marine Colloids Division, ﬁling of Food Additive Petitions;
Hercules, Inc.; Notice of Receipt of Citizen Petition;
Request for Comments. Fed Reg 57:49483–49485.
26. National Research Council. Food Chemical Codex. 2nd
ed, suppl 2. Washington, DC:National Academy of
Science, 1975.
27. National Research Council. Food Chemical Codex. 4th
ed. Washington, DC:National Academy of Science, 1996.
28. Tong H-K, Lee K-H, Wong H-A. The molecular weight
and viscosity of the water-soluble polysaccharide(s)
from Eucheuma spinosum. Carbohydr Res 81:1–6 (1980).
29. Weiner ML. Toxicological properties of carrageenan.
Agents Actions 32(1/2):46–51 (1991). 
30. Food and Drugs: Food Additives Permitted for Direct
Addition to Food for Human Consumption. 21 C.F.R.
172.620,172.626,172.655,172.660, 2000. 
31. Food and Drugs: Substances Generally Regarded as
Safe. 21 C.F.R. 182.7255, 1999. 
32. Food and Drugs: New Drugs. 21 C.F.R. 310.545, 1999. 
33. Food and Drugs: 21 C.F.R. 133.178, 133.179, 136.110,
139.121, 139.121, 139.122, 150.141, 150.161, 176.170 (2000). 
34. Watt J, McLean C, Marcus R. Degradation of car-
rageenan for the experimental production of ulcers in
the colon. J Pharm Pharmacol 31:645–646 (1979).
35. Marcus SN, Marcus AJ, Marcus R, Ewen SWB, Watt J.
The pre-ulcerative phase of carrageenan-induced
colonic ulceration in the guinea-pig. Int J Exp Pathol
73:515–526 (1992).
36. Sarwar G, Matoyoshi S, Oda H. Purification of a κ-car-
rageenase from marine cytophaga species. Microbiol
Immunol 31:869–877 (1987).
37. Weigl J, Yaphe W. The enzymic hydrolysis of car-
rageenan by pseudomonas carrageenovora: puriﬁcation
of a κ-carrageenase. Can J Microbiol 12:939–947 (1986).
38. Potin P, Sanseau A, LeGall Y, Rochas C, Bloareg B.
Purification and characterization of a new κ-car-
rageenase from a marine cytophaga-like bacterium. Eur
J Biochem 201:241–247 (1991).
39. McLean MW, Williamson FB. κ-Carrageenase from
Pseudomonas carrageenovora. Eur J Biochem
93:553–558 (1979).
40. Johnston KH, McCandless EL. Enzymic hydrolysis of the
potassium chloride soluble fraction of carrageenan: prop-
erties of “lambda carrageenases” from Pseudomonas
carrageenovora. Can J Microbiol 19(7):779–788 (1973).
41. Friedman LJ, Greenwald CG. Food additives. In:
Encyclopedia of Chemical Technology, Vol 11 (Howe-Grant
M, ed). 4th ed. New York:John Wiley & Sons, 1994;805–833. 
42. Meer WA. Plant hydrocolloids. In: Food Colloids (Graham
HD, ed). Westport, CT:AVI Publishing Company, Inc.,
1977;522–539.
43. Food and Nutrition Board, National Research Council.
The 1977 Survey of Industry on the Use of Food
Additives: Committee on GRAS List Survey–Phase III.
Part 3. PB 80–113418. Washington, DC:National Academy
of Sciences, 1979. 
44. Anderson W. Carrageenan: structure and biological
activity. Can J Pharm Sci 2:81–90 (1967). 
45. Comité “Additifs Alimentaires” du CNERNA. Toxicological
evaluation of carrageenans. 10-Conclusions: acquired
knowledges and problems requiring further researches.
Sciences des aliments 4:429–438.
46. Will R, Zuanich J, DeBoo A, Ishikawa Y. Water-soluble
polymers. Menlo Park, CA:Chemical Economics
Handbook - SRI International, 1999;582.0000E–582.0003V. 
47. Piculell L. Gelling carrageenans. In: Food Polysaccharides
and Their Applications. New York:Marcel Dekker, Inc.,
1995;205–244.
48. Food and Nutrition Board, National Research Council.
1977 Survey of Industry on the Use of Food Additives.
Summarized Data: Committee on GRAS List Survey–
Phase III. Washington, DC:National Academy of
Sciences, 1979;978–987.
49. Food Protection Committee, Food and Nutrition Board,
National Research Council. Chemicals Used in Food
Processing. Publication 1274. Washington, DC:National
Academy of Sciences, 1965;31–34. 
50. Corpet DE, Taché S, Préclaire M. Carrageenan given as
a jelly, does not initiate, but promotes the growth of
aberrant crypt foci in the rat colon. Cancer Lett 114:53–55
(1997).
51. Wilcox DK, Higgins J, Bertram TA. Colonic epithelial cell
proliferation in a rat model of nongenotoxin-induced
colonic neoplasia. Lab Invest 67:405–411 (1992). 
52. Kitsukawa Y, Saito H, Suzuki Y, Kasanuki J, Tamura Y,
Yoshida S. Effect of ingestion of eicosapentaenoic acid
ethyl ester on carrageenan-induced colitis in guinea
pigs. Gastroenterology 102:1859–1866 (1992).
53. Marcus AJ, Marcus SN, Marcus R, Watt J. Rapid pro-
duction of ulcerative disease of the colon in newly-
weaned guinea-pigs by degraded carrageenan. J Pharm
Pharmacol 41:423–426 (1989).
54. Ling K-Y, Bhalla D, Hollander D. Mechanisms of car-
rageenan injury of IEC18 small intestinal epithelial cell
monolayers. Gastroenterology 95:1487–1495 (1988).
55. Calvert RJ, Reicks M. Alterations in colonic thymidine
kinase enzyme activity induced by consumption of various
dietary ﬁbers. Proc Soc Exp Biol Med 189:45–51 (1988).
56. Delahunty T, Recher L, Hollander D. Intestinal permeabil-
ity changes in rodents: a possible mechanism for
degraded carrageenan-induced colitis. Food Chem
Toxicol 25:113–118 (1987).
57. Arakawa S, Okumua M, Yamada S, Ito M, Tejima S.
Enhancing effect of carrageenan on the induction of rat
colonic tumors by 1,2-dimethylhydrazine and its relation
to β-glucuronidase activities in feces and other tissues.
J Nutr Sci Vitaminol (Tokyo) 32:481–485 (1986).
58. Kitano A, Matsumoto T, Hiki M, Hashimura H, Yoshiyasu
K, Okawa K, Kuwajima S, Kobayashi K. Epithelial dyspla-
sia of the rabbit colon induced by degraded car-
rageenan. Cancer Res 46:1374–1376 (1986).
59. Fath RB, Deschner EE, Winawer SJ, Dworkin BM.
Degraded carrageenan-induced colitis in CF1 mice.
Digestion 29:197–203 (1984).
60. Mori H, Ohbayashi F, Hirono I, Shimada T, Williams GM.
Absence of genotoxicity of the carcinogenic sulfated
polysaccharide carrageenan and dextran sulfate in
mammalian DNA repair and bacterial mutagenicity
assays. Nutr Cancer 6:92–97 (1984). 
61. Nicklin S, Miller K. Effect of orally administered food-
grade carrageenans on antibody-mediated and cell-
mediated immunity in the inbred rat. Food Chem Toxicol
22:615–621 (1984).
62. Jensen BH, Andersen JO, Poulsen SS, Olsen PS,
Rasmussen SN, Hansen SH, Hvidberg DF. The prophylac-
tic effect of 5-aminosalicylic acid and salazosulphapyri-
dine on degraded-carrageenan-induced colitis in guinea
pigs. Scand J Gastroenterol 19:299–303 (1984).
63. Olsen PS, Kirkegaard P, Poulsen SS. The effect of ileo-
transversostomy on carrageenan-induced colitis in
guinea pig. Scand J Gastroenterol 18:407–410 (1983).
64. Kawaura A, Shibata M, Togei K, Otsuka H. Effect of
dietary degraded carrageenan on intestinal carcinogen-
esis in rats treated with 1,2-dimethylhydrazine dihy-
drochloride. Tokushima J Exp Med 29:125–129 (1982).
65. Hirono I, Sumi Y, Kuhara K, Miyakawa M. Effect of
degraded carrageenan on the intestine in germfree rats.
Toxicol Lett 8:207–212 (1981).
66. Norris AA, Lewis AJ, Zeitlin IJ. Inability of degraded car-
rageenan fractions to induce inﬂammatory bowel ulcer-
ation in the guinea pig. J Pharm Pharmacol 33:612–613
(1981).
67. Oohashi Y, Ishioka TT, Wakabayashi K, Kuwabara N. A
study of carcinogenesis induced by degraded car-
rageenan arising from squamous metaplasia of the rat
colorectum. Cancer Lett 14:267–272 (1981).
68. Olsen PS, Poulsen SS. Stereomicroscopic and histologic
changes in the colon of guinea pigs fed degraded car-
rageenan. Acta Pathol Microbiol Scand Sect A
88:135–141 (1980).
69. Rustia M, Shubik P, Patil K. Lifespan carcinogenicity
tests with native carrageenan in rats and hamsters.
Cancer Lett 11:1–10 (1980).
70. Oohashi Y, Kitamura S, Wakabayashi K, Kuwabara N,
Fukuda Y. Irreversibility of degraded carrageenan-
induced colorectal squamous metaplasia in rats. Gann
70:391–392 (1979).
Review • Harmful effects of carrageenan
Environmental Health Perspectives • VOLUME 109 | NUMBER 10 | October 2001 99371. Onderdonk AB, Hermos JA, Dzink JL, Bartlett JG.
Protective effect of metronidazole in experimental ulcer-
ative colitis. Gastroenterology 74:521–526 (1978).
72. Wakabayashi K, Inagaki T, Fujimoto Y, Fukuda Y.
Induction by degraded carrageenan of colorectal tumors
in rats. Cancer Lett 4:171–176 (1978).
73. Watanabe K, Reddy BS, Wong CQ, Weisburger JH.
Effect of dietary undegraded carrageenan on colon car-
cinogenesis in F344 rats treated with azoxymethane or
methylnitrosourea. Cancer Res 38:4427–4430 (1978).
74. Pittman KA, Golberg L, Coulston F. Carrageenan: the
effect of molecular weight and polymer type on its
uptake, excretion and degradation in animals. Food
Cosmet Toxicol 14:85–93 (1976).
75. Engster M, Abraham R. Cecal response to different mole-
cular weights and types of carrageenan in the guinea
pig. Toxicol Appl Pharmacol 38:265–282 (1976).
76. Mankes R, Abraham R. Lysosomal dysfunction in colonic
submucosal macrophages of rhesus monkeys caused by
degraded iota carrageenan. Proc Soc Exp Biol Med
150:166–170 (1975).
77. Iatropoulos MJ, Golberg L, Coulston L. Intestinal carcino-
genesis in rats using 1,2-dimethylhydrazine with or without
degraded carrageenan. Exp Mol Pathol 23:386–401 (1975).
78. Grasso P, Gangolli SD, Butterworth KR, Wright MG.
Studies on degraded carrageenan in rats and guinea-
pigs. Food Cosmet Toxicol 13:195–201 (1975).
79. Abraham R, Fabian RJ, Golberg MB, Coulston F. Role of
lysosomes in carrageenan-induced cecal ulceration.
Gastroenterology 67:1169–1181 (1974).
80. Van der Waaif D, Cohen BJ, Anver MR. Mitigation of
experimental inﬂammatory bowel disease in guinea pigs
by selective elimination of the aerobic gram-negative
intestinal microﬂora. Gastroenterology 67:460–472 (1974).
81. Poulsen E. Short-term peroral toxicity of undegraded car-
rageenan in pigs. Food Cosmet Toxicol 11:219–227 (1973).
82. Benitz K-F, Golberg L, Coulston F. Intestinal effects of
carrageenans in the rhesus monkey. Food Cosmet
Toxicol 11:565–575 (1973).
83. Grasso P, Sharratt M, Carpanini FMB, Gangolli SD.
Studies on carrageenan and large-bowel ulceration in
mammals. Food Cosmet Toxicol 11:555–564 (1973).
84. Fabian RJ, Abraham R, Coulston F, Golberg L.
Carrageenan-induced squamous metaplasia of the rec-
tal mucosa in the rat. Gastroenterology 65:265–276
(1973).
85. Abraham R, Golberg L, Coulston F. Uptake and storage of
degraded carrageenan in lysosomes of reticuloendothe-
lial cells of the rhesus monkey. Exp Mol Pathol 17:77–93
(1972). 
86. Watt J, Marcus R. Carrageenan-induced ulceration of the
large intestine in the guinea pig. Gut 12:164–171 (1971).
87. Marcus R, Watt J. Colonic ulceration in young rats fed
degraded carrageenan. Lancet 2:765–766 (1971).
88. Sharratt M, Grasso P, Carpanini F, Gangolli SD.
Carrageenan ulceration as a model for human ulcerative
colitis. Lancet 2:932 (1970). 
89. Watt J, Marcus R. Ulcerative colitis in rabbits fed
degraded carrageenan. J Pharm Pharmacol 22:130–131
(1970).
90. Watt J, Marcus R. Hyperplastic mucosal changes in the
rabbit colon produced by degraded carrageenin.
Gastroenterology 59:760–768 (1970).
91. Maillet M, Bonfils S, Lister RE. Carrageenan: effects in
animals. Lancet 2:414–415 (1970).
92. Watt J, Marcus R. Ulcerative colitis in the guinea-pig
caused by seaweed extract. J Pharm Pharmacol
21:187S–188S (1969).
93. Marcus R, Watt J. Seaweeds and ulcerative colitis in
laboratory animals. Lancet 2:489–490 (1969).
94. Onderdonk AB. The carrageenan model for experimental
ulcerative colitis. Prog Clin Biol Res 186:237–245 (1985).
95. Ottet NK. On animal models for inﬂammatory bowel dis-
ease. Gastroenterology 62:1269–1272 (1972).
96. Watt J, Marcus R. Progress report: Experimental ulcera-
tive disease of the colon in animals. Gut 14:506–510 (1973).
97. Sharratt M, Grasso P, Carpanini F, Gangolli SD.
Carrageenan ulceration as a model for human ulcerative
colitis. Lancet 1:192–193 (1971). 
98. Mottet NK. On animal models for inflammatory bowel
disease. Gastroenterology 62:1269–1271 (1971).
99. Kim H-S, Berstad A. Experimental colitis in animal mod-
els. Scand J Gastroenterol 27:529–537 (1992).
100. Watt J, Marcus SN, Marcus AJ. The comparative pro-
phylactic effects of sulfasalazine, prednisolone, and aza-
thioprine in experimental ulceration. J Pharm Pharmacol
32:873–874 (1980). 
101. Kitano A, Matsumoto T, Oshitani N, Nakagawa M,
Yasuda K, Watanabe Y, Tomobuchi M, Obayashi M,
Tabata A, Fukushima R, et al. Distribution and anti-
inflammatory effect of mesalazine on carrageenan-
induced colitis in the rabbit. Clin Exp Pharmacol Physiol
23:305–309 (1996). 
102. Ishioka T, Kuwabara N, Oohashi Y, Wakabayashi K.
Induction of colorectal tumors in rats by sulfated poly-
saccharides. CRC Crit Rev Toxicol 17:215–244 (1987).
103. Gangolli SD, Wright MG, Grasso P. Identiﬁcation of car-
rageenan in mammalian tissues: an analytical and histo-
chemical study. Histochem J 5:37–48 (1973). 
104. Pipy B. 9-Carraghénanes et macrophages. Sciences des
aliments 4:415–428 (1984). 
105. Catanzaro PJ, Schwartz HJ, Graham RD. Spectrum and
possible mechanism of carrageenan cytotoxicity. Am J
Pathol 64:387–404 (1971). 
106. Thomson AW, Fowler EF. Carrageenan: a review of its
effect on the immune system. Agents Actions 1:265–273
(1981). 
107. Kolodny EW, Fluharty AL. Metachromatic leukodystrophy
and multiple sulfatase deficiency: sulfatide lipidosis. In:
The Metabolic and Molecular Bases of Inherited Diseases
(Scriver CR, AL Beaudet AL, Sly WS, Valle D, eds). 7th ed.
New York: McGraw-Hill, Inc., 1995; 2693–2739.
108. Ballabio A, Shapiro LJ. Steroid sulfatase deﬁciency and
X-linked ichthyosis. In: The Metabolic and Molecular
Bases of Inherited Diseases (Scriver CR, Beaudet AL, Sly
WS, Valle D, eds) 7th ed. New York: McGraw-Hill, Inc.,
1995;2999–3022.
109. Cotran RS, Kumar V, Robbins SL, Schoen FJ. Genetic dis-
eases. Robbins’ Pathological Basis of Disease. 5th ed.
Philadelphia:W.B. Saunders Company, 1994;123–171.
110. Muenzer J. Mucopolysaccharidoses. Adv Pediatr
33:269–302 (1986).
111. Corpet DE. Toxicological evaluation of carrageenans. 5-
Dietary carrageenans and intestinal microflora.
Sciences des aliments 4:367–374 (1984).
112. Michel C, Macfarlane GT. Digestive fates of soluble poly-
saccharides from marine macroalgae: involvement of the
colonic microflora and physiological consequences for
the host. J Appl Bacteriol 1996;80:349–369 (1996).
113. Gibson GR, Macfarlane S, Cummings JH. The fer-
mentability of polysaccharides by mixed human faecal
bacteria in relation to their suitability as bulk-forming
laxatives. Lett Appl Microbiol 11:251–254 (1990).
114. Roediger WEW, Duncan A, Kapaniris O, Millard S.
Reducing sulfur compounds of the colon impair colono-
cytes nutrition: implications for ulcerative colitis.
Gastroenterology 104:802–809 (1993).
115. Richardson CJ, Magee EAM, Cummings JH. A new
method for the determination of sulphide in gastrointesti-
nal contents and whole blood by microdistillation and ion
chromatography. Clin Chim Acta 293:115–125 (2000).
116. Babidge W, Millard S, Roediger W. Sulﬁdes impair short
chain fatty acid beta-oxidation at acyl-CoA dehydroge-
nase level in colonocytes: implications for ulcerative col-
itis. Mol Cell Biochem 181:117–124 (1998).
117. Toscani A, Soprano DR, Soprano KJ. Molecular analysis
of sodium butyrate-induced growth arrest. Oncogene
Res 3:223–238 (1998).
118. Glinghammar B, Holmberg K, Rafter J. Effects of colonic
lumenal components on AP-1 dependent gene transcrip-
tion in cultured human colon carcinoma cells.
Carcinogenesis 20:969–976 (1999). 
119. Salyers AA, West SHE, Vercelotti JR, Wilkins TD.
Fermentation of mucins and plant polysacchairds by
anerobic bacteria from the human colon. Appl Environ
Microbiol 334:529–533 (1977).
120. Di Rosa M. Review: Biological properties of car-
rageenan. J Pharm Pharmacol 24:89–102 (1972).
121. Hoffman R. Carrageenans inhibit growth-factor binding.
Biochem J 289:331–334 (1993).
122. Cochran FR, Baxter CS. Macrophage-mediated suppres-
sion of T-lymphocyte proliferation induced by oral car-
rageenan administration. Immunology 53:221–227 (1984).
123. Thomson AW, Fowler EF. Potentiation of tumor growth by
carrageenan. Transplantation 24:397–400 (1977).
124. Carlucci MJ, Pujol CA, Ciancia M, Noseda MD,
Matulewicz MC, Damonte EB, Cerezo AS. Antiherpetic
and anticoagulant properties of carrageenans from the
red seaweed Gigartina skottsbergii and their cyclized
derivatives: correlation between structure and biological
activity. Int J Biol Macromol 20:97–105 (1997).
125. Yamada T, Ogano A, Saito T, Watanabe J, Uchiyama H,
Nakagawa Y. Preparation and anti-HIV activity of low-
molecular-weight carrageenans and their sulfated deriv-
atives. Carbohydr Polym 32:51–55 (1997).
126. Pearce-Pratt R, Phillips DM. Sulfated polysaccharides
inhibit lymphocyte-to-epithelial transmission of human
immunodeﬁciency virus-1. Biol Reprod 54:173–182 (1996).
127. Zaretzky FR, Pearce-Pratt R, Phillips DM. Sulfated
polyanions block Chlamydia trachomatis infection of
cervix-derived human epithelia. Infect Immun
63:3520–3526 (1995).
128. Hoffman R, Burns WW, Paper DH. Selective inhibition of
cell proliferation and DNA synthesis by the polysul-
phated carbohydrate ι-carrageenan. Cancer Chemother
Pharmacol 36:325–334 (1995).
129. Coombe DR, Parish CR, Ramshaw IA, Snowden JM.
Analysis of the inhibition of tumour metastasis by sul-
phated polysaccharides. Int J Cancer 39:82–88 (1987). 
130. Tobacman JK. Filament disassembly and loss of mam-
mary myoepithelial cells after exposure to lambda-car-
rageenan. Cancer Res 57:2823–2826 (1997). 
131. Tobacman JK, Walters K. Carrageenan exposure leads
to mammary myoepithelial cell development of unusual
intracellular inclusions. Proc Am Assoc Cancer Res
39:4722 (1999).
132. Cater DB. The carcinogenic action of carrageenin in
rats. Br J Cancer 15:607–614 (1961).
133. Hopkins J. Carcinogenicity of carrageenan. Food Cosmet
Toxicol 19:779–788 (1981).
134. Dyrset N, Lystad KQ, Levine DW. Development of a fer-
mentation process for production of a kappa-car-
rageenase from Pseudomonas carrageenovora. Enzyme
Microb Technol 20(6):418–423 (1997).
135. Irvine EJ, Farrokhyar F, Swarbrick ET. A critical review of
epidemiological studies in inflammatory bowel disease.
Scand J Gastroenterol 36(1):2–15 (2001).
136. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000:
Cancer Incidence, Mortality and Prevalence Worldwide,
Version 1.0. IARCCancerBase No. 5. Lyon:IARC Press,
2001. Limited version available: http://www-dep.iarc.fr/cgi-
bin/exe-globom.exe [cited 2 March 2001]. 
137. Gold LS, Slone TH, Manley NB, Garﬁnkel GB, Rohrbach L,
Ames BN. Carcinogenic potency database. In: Handbook
of Carcinogenic Potency and Genotoxicity Databases
(Gold LS, Zeiger E, eds). New York:CRC Press, Inc.,
1997;116–117.
138. Gold LS, Slone TH, Ames BN. Summary of carcingogenic
potency database by chemical. In: Handbook of
Carcinogenic Potency and Genotoxicity Databases (Gold
LS, Zeiger E, eds). New York:CRC Press, Inc., 1997;629.
139. Food Additives Amendment of 1958. Public Law 85–929,
72 Stat. 1784. 
140. Food Quality Protection Act of 1996. Public Law 104–170,
110 Stat. 1489. 
Review • Tobacman
994 VOLUME 109 | NUMBER 10 | October 2001 • Environmental Health Perspectives